Oral doxycycline for Lyme neuroborreliosis with symptoms of encephalitis, myelitis, vasculitis or intracranial hypertension

European Journal of Neurology

Volumn 21, Issue 9, 2014, Pages 1162-1167

  Bremell, D ^a   Dotevall, L ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Department of Communicable Disease Control Västra Götaland Region ^*  (Sweden)

Author keywords

Central nervous system Lyme disease; Doxycycline; Lyme borreliosis; Lyme neuroborreliosis

Indexed keywords

DOXYCYCLINE; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; DISEASE SEVERITY; ENCEPHALITIS; FEMALE; HUMAN; INFANT; INTRACRANIAL HYPERTENSION; LYME DISEASE; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MYELITIS; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT OUTCOME; VASCULITIS; VERY ELDERLY; ADOLESCENT; CEREBROSPINAL FLUID; CHILD; COMPLICATION; LYME NEUROBORRELIOSIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; DOXYCYCLINE; ENCEPHALITIS; FEMALE; HUMANS; INTRACRANIAL HYPERTENSION; LYME NEUROBORRELIOSIS; MALE; MIDDLE AGED; MYELITIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULITIS; YOUNG ADULT;

EID: 84905022916     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12420     Document Type: Article

References (19)

1. Mygland Ã, Ljøstad U, Fingerle V, et al. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 2010; 17: 8-16.
2. Rupprecht TA, Fingerle V. Neuroborreliosis: pathogenesis, symptoms, diagnosis and treatment. Future Neurol 2011; 6: 273-289.
3. Fallon BA, Levin ES, Schweitzer PJ, Hardesty D. Inflammation and central nervous system Lyme disease. Neurobiol Dis 2010; 37: 534-541.
4. Oschmann P, Dorndorf W, Hornig C, Schäfer C, Wellensiek HJ, Pflughaupt KW. Stages and syndromes of neuroborreliosis. J Neurol 1998; 245: 262-272.
5. Kaiser R. [Clinical courses of acute and chronic neuroborreliosis following treatment with ceftriaxone]. Nervenarzt 2004; 75: 553-557.
6. Stanek G, Fingerle V, Hunfeld KP, et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect 2011; 17: 69-79.
7. Hansen K, Lebech AM. The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985-1990. A prospective study of 187 patients with Borrelia burgdorferi specific intrathecal antibody production. Brain 1992; 115(Pt 2): 399-423.
8. Cepok S, Zhou D, Vogel F, et al. The immune response at onset and during recovery from Borrelia burgdorferi meningoradiculitis. Arch Neurol 2003; 60: 849-855.
9. Borg R, Dotevall L, Hagberg L, et al. Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis. Scand J Infect Dis 2005; 37: 449-454.
10. Ljøstad U, Skogvoll E, Eikeland R, et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol 2008; 7: 690-695.
11. Venkatesan A, Tunkel AR, Bloch KC, et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis 2013; 57: 1114-1128.
12. Berglund J, Stjernberg L, Ornstein K, Tykesson-Joelsson K, Walter H. 5-y follow-up study of patients with neuroborreliosis. Scand J Infect Dis 2002; 34: 421-425.
13. Vrethem M, Hellblom L, Widlund M, et al. Chronic symptoms are common in patients with neuroborreliosis - a questionnaire follow-up study. Acta Neurol Scand 2002; 106: 205-208.
14. Ljøstad U, Mygland Ã. Remaining complaints 1 year after treatment for acute Lyme neuroborreliosis; frequency, pattern and risk factors. Eur J Neurol 2010; 17: 118-123.
15. Halperin JJ, Shapiro ED, Logigian E, et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007; 69: 91-102.
16. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43: 1089-1134.
17. Dotevall L, Hagberg L. Penetration of doxycycline into cerebrospinal fluid in patients treated for suspected Lyme neuroborreliosis. Antimicrob Agents Chemother 1989; 33: 1078-1080.
18. Kan L, Sood SK, Maytal J. Pseudotumor cerebri in Lyme disease: a case report and literature review. Pediatr Neurol 1998; 18: 439-441.
19. Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002; 26: 1492-1495.